India  

Bharat Biotech

Indian multinational biotechnology company and vaccine manufacturer

Bharat Biotech    ▸ Facts   ▸ Comments   ▸ News   ▸ Videos   

Bharat Biotech: Indian multinational biotechnology company and vaccine manufacturer
Bharat Biotech International Limited (BBIL) is an Indian multinational biotechnology company headquartered in the city of Hyderabad, India engaged in the drug discovery, drug development, manufacture of vaccines, bio-therapeutics, pharmaceuticals and health care products.

0
shares
ShareTweetSavePostSend
 
Health Minister launches India’s first nasal COVID-19 vaccine ‘iNCOVACC’ | Oneindia News [Video]

Health Minister launches India’s first nasal COVID-19 vaccine ‘iNCOVACC’ | Oneindia News

Union Health Minister Dr Mansukh Mandaviya and Science and Technology Minister Jitendra Singh launched India's first nasal COVID-19 vaccine - 'iNCOVACC' on Thursday. The nasal COVID-19 vaccine has been..

Credit: Oneindia     Duration: 01:58Published
Bharat Biotech to launch first ever intranasal Covid-19 vaccine on 26th January| Oneindia News *News [Video]

Bharat Biotech to launch first ever intranasal Covid-19 vaccine on 26th January| Oneindia News *News

India’s vaccine manufacturer Bharat Biotech to launch first ever intranasal Covid-19 vaccine on 26th January. #Covid19vaccine #BharatBioTech #NasalVaccine

Credit: Oneindia     Duration: 01:45Published
UN records almost 18,000 civilian casualties in Ukraine since Russian invasion | Oneindia News*News [Video]

UN records almost 18,000 civilian casualties in Ukraine since Russian invasion | Oneindia News*News

Bharat Biotech's nasal vaccine to be available on CoWIN app from today; Shelly Oberoi named Delhi Mayor candidate of AAP; People advised to wear masks by government, it’s not mandatory for now;..

Credit: Oneindia     Duration: 02:37Published
Covid drills held across cities, Hospital checks conducted | Oneindia News *News [Video]

Covid drills held across cities, Hospital checks conducted | Oneindia News *News

Covid drills held across cities, Hospital checks conducted; Bharat Biotech announces price of intranasal Covid vaccine; The 6th edition of the joint exercise of the Indian Army & Kazakhstan Army KazInd..

Credit: Oneindia     Duration: 03:28Published
Bharat Biotech's intranasal Covid vaccine to be available on CO-WIN from today | Oneindia News*News [Video]

Bharat Biotech's intranasal Covid vaccine to be available on CO-WIN from today | Oneindia News*News

Bharat Biotech's nasal vaccine to be available on CoWIN app from today; Shelly Oberoi named Delhi Mayor candidate of AAP; People advised to wear masks by government, it’s not mandatory for now;..

Credit: Oneindia     Duration: 02:25Published

You Might Like


Covid-19: Health Minister launches Bharat Biotech's first India-made nasal vaccine, all you need to know

The first nasal Covid-19 vaccine developed in India by Bharat Biotech, iNCOVACC launches on the 74th Republic Day.
DNA - Published

Centre launches Bharat Biotech's iNCOVACC, India's first nasal Covid vaccine

On the occasion of Republic Day, India got its first-ever intranasal vaccine iNCOVACC, which will be manufactured by Hyderabad-based Bharat Biotech.The vaccine, dubbed "game changer" by some experts,..
IndiaTimes - Published

India gets first nasal Covid vaccine: How it can be the 'game changer'

Centre on Thursday launched India's first nasal Covid-19 vaccine iNCOVACC. Bharat Biotech's Incovacc received government approval for use as a booster dose in the country-wide mass inouclation program...
IndiaTimes - Published

Covid-19: Bharat Biotech's iNCOVACC nasal vaccine to hit markets from February; know prices, eligibility

Bharat Biotech's iNCOVACC will be the country of India's first needleless booster shot which will be available in private hospitals.
DNA - Published

First nasal vaccine for Covid-19, Bharat Biotech's iNCOVACC, to be launched on January 26

Bharat Biotech will offer the intranasal vaccine for Rs 325 to the government and Rs 800 to private hospitals.
DNA - Published

First Indian intranasal Covid vaccine to be launched on January 26

Homegrown vaccine maker Bharat Biotech will launch its intranasal Covid-19 vaccine iNCOVACC, the first of its kind in India, on January 26, the company's chairman and managing director Krishna Ella..
IndiaTimes - Published

Ocugen-Bharat Biotech Covid vaccine Covaxin meets main goals in US trial

Ocugen Inc said on Monday the Covid-19 vaccine developed by its Indian partner Bharat Biotech International Ltd met the main goals of a trial in the United States. The vaccine, sold under brand name..
IndiaTimes - Published

Amid Covid BF.7 scare in India, know who is eligible to get Bharat Biotech nasal vaccine booster dose

The booster dose of the Bharat Biotech intranasal Covid vaccine is now available on the CoWIN platform and can be booked by eligible populations.
DNA - Published

Bharat Biotech's nasal vaccine at Rs 800 for private centres and Rs 325 for govt hospitals

Bharat Biotech’s intranasal Covid-19 vaccine iNCOVACC will be priced at Rs 800 per dose in private markets and at Rs 325 per dose for procurement by central and state governments, the vaccine maker..
IndiaTimes - Published

Covid 4th wave scare in India: Bharat Biotech reveals price of nasal vaccine, check how to book booster dose online

Bharat Biotech has revealed the price of its intranasal Covid vaccine amid 4th wave scares, and the booster dose of the same can been booked online.
DNA - Published

Bharat Biotech's nasal vaccine to be priced at Rs 800/dose in pvt markets, Rs 325/dose for governments

Bharat Biotech on Tuesday said that its intranasal Covid-19 vaccine iNCOVACC will be priced at Rs 800 per dose for the private markets and Rs 325 per dose for central and state governments. The company..
IndiaTimes - Published

'Bharat Biotech annonces price of nasal vaccine': Covid-19 key points


IndiaTimes - Published

Bharat Biotech's nasal Covid vaccine can be used as booster: Regulator


IndiaTimes - Published

World's first intranasal Covid vaccine from Bharat Biotech gets CDSCO approval

iNCOVACC: Bharat Biotech said that launch dates, pricing and availability will be announced in due course of time.
DNA - Published

Bharat Biotech's intranasal Covid-19 vaccine iNCOVACC gets CDSCO nod for heterologous booster doses


IndiaTimes - Published Also reported by •DNA

Bharat Biotech's Intranasal Covid-19 Booster gets DCGI nod for emergency use

For individuals 18 years of age and older, the DCGI has authorised the use of Bharat Biotech's five arms heterologous booster, ANI reported.
DNA - Published

Indian govt, Bharat Biotech rubbish reports of Covaxin development being rushed under political pressure


IndiaTimes - Published

Bharat Biotech's Covid-19 nasal vaccine approved for restricted use in India

Bharat Biotech's Covid-19 recombinant nasal vaccine has been approved by the Indian drug regulator, the country's health minister Mansukh Mandaviya tweeted on Tuesday.
IndiaTimes - Published Also reported by •DNA

Bharat Biotech submits intranasal vaccine data to drug regulator, says vax safe and immunogenic

Bharat Biotech International Limited (BBIL) on Monday said its intranasal Covid-19 vaccine BBV154 has proved to be safe, well-tolerated, and immunogenic in subjects in controlled clinical trials for..
IndiaTimes - Published

Bharat Biotech expects regulator's nod for intranasal Covid-19 vaccine in August

Bharat Biotech, which is working on an intranasal Covid-19 vaccine candidate is hopeful of getting regulatory licenses this month, if all goes well, chairman and managing director of the company,..
IndiaTimes - Published

Biological E's Corbevax, Bharat Biotech's Covaxin get NTAGI's nod for use children aged 5-12 years

Prime Minister Narendra Modi emphasised that all eligible children get the Covid-19 vaccine as soon as possible via "special programmes" in schools.
DNA - Published

Bharat Biotech's Covid-19 nasal vaccine phase III trials completed

In an exclusive interview with ANI, Dr Ella said, "We just completed a clinical trial, a data analysis is going on. Next month, we will submit the data to the regulatory agency. If everything is okay,..
IndiaTimes - Published

Covaxin safe for 2-18 age group: BB study

It conducted phase II/III, open-label, and multicentre study to evaluate the safety, reactogenicity and immunogenicity of Covaxin in children and adolescents in the 2-18 years of age group between..
IndiaTimes - Published

Covaxin booster dose enhances vaccine effectiveness against Delta, Omicron variants, says ICMR study

The protective efficacy of Bharat Biotech's Covaxin following two and three-dose immuniszations against the Delta variant and the efficacy of the Covaxin against Omicron variants were studied in a..
IndiaTimes - Published

FDA lifts hold on Covaxin's clinical trials in US

The US Food and Drug Administration which has put on hold the phase 2/ 3 clinical trials of Bharat Biotech's Covid-19 vaccine Covaxin, in USA, has lifted the pause, according to a statement issued by..
IndiaTimes - Published

Covaxin Phase 2&3 trials to resume in US after USFDA lifts clinical hold

The US Food and Drug Administration (USFDA) has lifted the clinical hold on the Phase 2 and 3 immuno-bridging clinical trials of Bharat Biotech’s Covid-19 vaccine Covaxin that were being conducted in..
IndiaTimes - Published

CEPI partners consortium of Bharat Biotech, Sydney University & ExcellGene to develop variant-proof SARS-CoV-2 vaccine


IndiaTimes - Published

Bharat Biotech seeks DCGI nod for phase 2/3 Covaxin booster trial among two to 18-year-old

Bharat Biotech has sought permission from India's drug regulator to conduct a phase 2/3 study of its Covid vaccine Covaxin as a booster dose among those aged two to 18 years, sources told PTI...
IndiaTimes - Published

MEA asked Bharat Biotech to act on WHO suspension? Officials refute claim


IndiaTimes - Published

Bharat Biotech must address WHO's Covaxin suspension to avoid EUL cancellation, says MEA

Weeks after WHO suspended the supply of Covaxin through UN procurement agencies, the MEA suggested that vaccine-maker Bharat Biotech addresses the issue immediately to avoid cancellation of the world..
IndiaTimes - Published

DCGI gives approval for Bharat Biotech's Covaxin for children aged 6-12

The Drug Controller General of India (DCGI) has given a restricted emergency use approval for Bharat Biotech's Covid-19 vaccine, Covaxin, for children between the age of six and 12. A Subject Expert..
IndiaTimes - Published Also reported by •DNA

DCGI grants approval to Corbevax for kids aged 5-12, Covaxin for 6-12 age group

The Drug Controller General of India (DCGI) on Tuesday granted emergency use approval to Covid-19 vaccines, Covaxin and Corbevax, for children below 12. Bharat Biotech's Covaxin has got nod for use in..
IndiaTimes - Published

Bharat Biotech asked to provide more data on Covid-19 vaccine Covaxin for children aged below 12

The Subject Expert Committee (SEC) of the Drug Controller General of India (DCGI) has asked Bharat Biotech for additional data on its Covid-19 vaccine, Covaxin, for administering it to children aged..
IndiaTimes - Published

Fallout of WHO observations: Covaxin's Phase 2/3 trials in US put on hold

The US Food and Drug Administration has put on hold the phase 2/3 clinical trials of Bharat Biotech's Covid-19 vaccine Covaxin, in USA. Bharat Biotech's partner for US and Canada for Covaxin, the FDA's..
IndiaTimes - Published

Bharat Biotech, SII slash prices of Covaxin, Covishield booster dose to Rs 225 per shot


IndiaTimes - Published

Covishield, Covaxin prices slashed ahead of booster drive expansion

Serum Institute of India has reduced the price of its Covishield vaccine from Rs 600 to Rs 225 per dose for private hospitals, the vaccine maker announced on Saturday. Bharat Biotech also slashed the..
IndiaTimes - Published

Japan recognises Covaxin to facilitate travel from April 10: Bharat Biotech


IndiaTimes - Published

'Amid drop in demand, Bharat Biotech slowed Covaxin production since February'


IndiaTimes - Published

No impact of WHO action on Covaxin, have not supplied to any UN agency: Bharat Biotech

With WHO announcing the suspension of Covaxin supply through UN procurement agencies, Bharat Biotech sources said on Monday the pharma company has not supplied the COVID-19 vaccine to any UN agency and..
IndiaTimes - Published

SII's Covovax becomes the fourth jab to be used for vaccination of 12-17 age group

Covovax is the 4th Covid vaccine authorised for administration in 12 years and above after ZyCoV-D, Bharat Biotech's Covaxin, Biological E's Corbevax.
DNA - Published

WHO suspends Covaxin supply for UN procurement citing GMP deficiencies at Bharat Biotech facilities


IndiaTimes - Published

Will Covid-19 nasal vaccine prove effective against infection? AIIMS expert says THIS

AIIMS expert Dr Sanjay Rai talked about the effectiveness of the Bharat Biotech nasal vaccine against the Covid-19 infection.
DNA - Published

Covaxin showed better antibody response in 2-18 year olds than adults: Bharat Biotech


IndiaTimes - Published

'Precautionary dose' for 60+ with comorbidities 9 months after 2nd dose - Check new guidelines

Bharat Biotech's Covaxin has been granted approval for restricted use in an emergency situation in the age group between 12 and 18 years.
DNA - Published

Documents required to register children between 15-18 years on CoWIN App - Complete list here

Meanwhile, Bharat Biotech received the nod from the DGCI for emergency use of vaccines in children above the age of 12 years.
DNA - Published

BREAKING: Bharat Biotech gets DGCI approval for emergency vaccination for kids aged 12-18

Amid rising cases of Omicron in India, DGCI has given Bharat Biotech a green signal for the emergency use of its vaccine for kids aged between 12 to 18 years.
DNA - Published

Bharat Biotech seeks DCGI's nod for its intranasal COVID-19 booster dose clinical trials

The company is hoping for early approval for the trails of the intranasal COVID-19 booster given the fast spread of the Omicron variant.
DNA - Published Also reported by •IndiaTimes

Covishield production capacity 250-275 million doses a month, Covaxin 50-60 million: MoS Health

The current vaccine production capacity of Covishield, manufactured by the Serum Institute of India, is approximately 250-275 million doses per month while it is about 50-60 million doses per month for..
IndiaTimes - Published


 Page 1  〉